Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "head and neck carcinoma" wg kryterium: Temat


Wyświetlanie 1-3 z 3
Tytuł:
THE EFFECT OF NICLOSAMIDE ON THE HEAD AND NECK CARCINOMA CELLS SURVIVAL AND THE EXPRESSION OF WNT/β-CATENIN SIGNALING AND GLYCOLYSIS PATHWAY COMPONENTS
Autorzy:
Kleszcz, Robert
Paluszczak, Jarosław
Baer-Dubowska, Wanda
Powiązania:
https://bibliotekanauki.pl/articles/895272.pdf
Data publikacji:
2019-08-30
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
Wnt signaling
glycolysis
β-catenin
niclosamide
head and neck carcinoma
Opis:
The aim of this study was to evaluate the effect of niclosamide, an antihelminthic drug recently identified as potential anti-cancer agent, on head and neck squamous carcinoma cells (HNSCC) viability, cell cycle distribution and apoptosis. The expression of key components of Wnt (CTNNB1, GSK-3β, CCND1, c-MYC, MMP7, BIRC5, Axin2) and glycolysis (GLUT1, MCT1, HK2, PFKM, PKM2, PDHA1, PDK1, LDHA) pathways was also examined to assess possible involvement in niclosamide anti-carcinogenic activity. HNSCC cells (FaDu, BICR6, H314 lines) were used in the research. Niclosamide treatment affected hypopharyngeal FaDu cells to the most extent (IC50 = 0.40 µM), while H314 cells derived from the floor of mouth were the least sensitive (IC50 = 0.94 µM). In FaDu cells the increased percentage of the cells in the S phase was observed along with the induction of apoptosis. Treatment with niclosamide in FaDu cells reduced the expression of MMP7 and the majority of glycolytic genes except increased LDHA. These results indicate that niclosamide is efficient inhibitor of HNSCC cells viability, however this effect depends on the cell type. In FaDu cells, the most sensitive to its anti-proliferative effect and prone to cell cycle arrest and apoptosis, this effect might be related to slightly modulation of canonical Wnt signaling and increased expression of LDHA.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 4; 661-669
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade
Autorzy:
Przybylski, Krzysztof
Majchrzak, Ewa
Weselik, Liucija
Golusiński, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1398281.pdf
Data publikacji:
2018
Wydawca:
Index Copernicus International
Tematy:
head and neck squamouscell carcinoma
immunotherapy
CTLA - 4
PD - 1
nivolumab
pembrolizumab
Opis:
Treating patients with squamous cell carcinoma of the head and neck is a significant problem. There is an increase in the incidence of malignant neoplasms in this region. Surgery, radiotherapy and chemotherapy are often not sufficient methods of treatment. Thorough analysis of processes occurring in the tumor microenvironment has allowed to distinguish three stages that make up the reaction of the human body to hostile antigens, which are tumor antigens. Understanding these mechanisms has resulted in the introduction of a new term immune-oncology. It is an area of cancer treatment that focuses on use of the patient’s immune system to combat the disease. Immunotherapy has had positive effects in cancer patients. The use of immune checkpoint inhibitors, such as anti-CTLA-4 and PD-1 monoclonal antibodies has enabled the modulation of T cell functions, consequently eliminating immunosuppression in the tumor microenvironment. Clinical trials were conducted using nivolumab and ipilimumab, which confirmed their clinical usefulness. The approval by FDA of nivolumab in treatment of recurrent and metastatic squamous cell carcinoma of the head and neck has increased the overall survival time of patients as well as disease free survival. Statistical data indicate an advantage of immunotherapy over other treatment methods at an advanced stage of cancer. This work aims to discuss basic issues related to immunotherapy, in particular immunotherapy in patients with squamous cell carcinoma of the head and neck.
Źródło:
Polish Journal of Otolaryngology; 2018, 72, 6; 10-16
0030-6657
2300-8423
Pojawia się w:
Polish Journal of Otolaryngology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Neuroendocrine Carcinoma of the Head and Neck – review of literature
Autorzy:
Berger, G
Dawidziuk, T
Chyczewski, L
Powiązania:
https://bibliotekanauki.pl/articles/1401521.pdf
Data publikacji:
2016
Wydawca:
Index Copernicus International
Tematy:
neuroendocrine carcinoma
head and neck
Opis:
Neuroendocrine carcinoma is a rare neoplasm, and its most common location in the head and neck area is the larynx, especially the epiglottis and the supraglottic region. The first case of neuroendocrine carcinoma of the larynx was reported in 1969 by Goldman et al. Expression of the two crucial markers, synaptophysin and chromogranin, along with neural cell adhesion molecule (CD56) should be mentioned among the neuroendocrine features detected on immunohistochemistry. Human papilloma virus (HPV16/18) infection in the laryngeal neuroendocrine carcinoma can be one of the causal factors, and the detection of HPV should be considered as a standard procedure for the diagnosis and treatment.
Źródło:
Polski Przegląd Otorynolaryngologiczny; 2016, 5, 4; 16-21
2084-5308
2300-7338
Pojawia się w:
Polski Przegląd Otorynolaryngologiczny
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies